GlassScriptPhysician profile
Dana Rifai
NPI 1780972059
$524.60
in general payments reported to CMS, 2019-2025
12 companies · $87.06 in 2025
The $87.06 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2020: $17.31 · 2021: $37.33 · 2022: $38.36 · 2023: $85.29 · 2024: $132 · 2025: $87.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $240 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $239.91 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $140.66 | 2019-2025 | Ozempic |
| Amgen INC. | $83.09 | 2022-2024 | Repatha, Otezla |
| Lilly USA, LLC | $60.00 | 2019-2025 | Zepbound, Mounjaro |
| Corium, LLC | $59.49 | 2024 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.17 | 2019 | |
| Abbvie INC. | $32.76 | 2025 | |
| Novartis Pharmaceuticals Corporation | $20.62 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $19.49 | 2021 | |
| Mylan Specialty L.P. | $17.31 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.44 | 2024 | Quviviq |
| Dexcom, INC. | $13.25 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Rifai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.